stockrow
Friday 6 November 2026
Export TNGX’s income statement to Excel — free account
Tango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
21.50
0.63
+3.02%
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Total debt
Tango Therapeutics, Inc.'s total debt at the end of fiscal 2022 was $41.1M, up 2,636.6% from $1.5M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $39.5M. Tango Therapeutics, Inc. ranks 140th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $41.1M | 2,636.59% |
| FY2021 | $1.5M | (80.94%) |
| FY2020 | $7.9M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $39.5M | (0.96%) |
| Jun 2023 | $39.9M | (3.59%) |
| Mar 2023 | $41.4M | 0.59% |
| Dec 2022 | $41.1M | 0.99% |
| 6 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| ABCL AbCellera Biologics Inc. compare | $81.0M |
| IRON Disc Medicine, Inc. compare | $59.3M |
| RLAY Relay Therapeutics, Inc. compare | $55.0M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $48.1M |
| TNGX Tango Therapeutics, Inc. | $39.5M |
| XENE Xenon Pharmaceuticals Inc. compare | $11.0M |
| PBLS Parabilis Medicines, Inc. compare | $6.8M |
| EWTX Edgewise Therapeutics, Inc. compare | $5.6M |
| IOVA Iovance Biotherapeutics, Inc. compare | $1.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement